Novavax (NVAX): a super-risky investment value propositionWhile Novavax has some positives, it is not a good candidate for new money. Novavax's two marquee programs, RSV F for maternal vaccination and NanoFlu are not doing particularly well, as they are getting delayed.
RSV F for maternal vaccination is now in Phase 3, but many investors are wondering if it's a viable drug. Even if Novavax successfully meets the development challenges, it may face strong competition from other biotech companies.
One possibility for Novovax is to be bought out, in which case the stock may be underpriced.
www.finstead.com
